The system connects global market signals with organizational expertise to deliver prioritized, function-specific roadmaps for biopharma leaders.
Boston, United States / September 30, 2026 — What’s Next for Pharma, built with a vision to deliver integrated leadership and pharmaceutical innovation, today unveiled BioPharmaGPS, an AI-driven system designed to move the biotech and pharmaceutical industry from silos to integration. BioPharmaGPS is the first in a planned series of products built for critical inflection points in the pharmaceutical product lifecycle, advancing the company’s vision of an ecosystem where human expertise and intelligent systems enrich each other.
Built by industry insiders, BioPharmaGPS runs on a proprietary model that aggregates signals across five key pharmaceutical markets – India, the EU, China, Japan, and the US – and delivers integrated, actionable insight to leaders in R&D, Clinical, CMC, Commercial, and Regulatory functions. The platform takes decision-makers from signal to logic to outcome through three layers:
The Signal Layer (the “what”): Real-time ingestion of global clinical trials, regulatory approvals and sentiment, new indications, and category shifts across the industry.
The Logic Layer (the “so what”): Cross-referencing of those signals against each user’s portfolio programs, ranked by immediate, near-term, or long-term relevance.
The Outcome Layer (the “now what”): Integrated strategic and operational priority roadmaps tailored to each function, with recommended recalibrations as cross-market signals shift.
Decision-makers are inundated with information from external intelligence sources and internal expertise, yet lack a way to connect it into clear priorities. BioPharmaGPS is designed to close that gap. Industry leaders have recognized the scale of the opportunity and described the platform as a need-to-have rather than a nice-to-have.
“The next wave of pharmaceutical approval and adoption needs a new approach, one rooted in the power of networked decisions. BioPharmaGPS is built to deliver precise, prioritized outcomes, merging organizational expertise with cross-market signals and translating that connectivity into decisions that move programs forward,” said Samiksha Shah, Founder of What’s Next for Pharma.
BioPharmaGPS is available through seat-based institutional access and organizational co-development partnerships. Learn more at whatsnextforpharma.com
About What’s Next for Pharma
What’s Next for Pharma was created with a vision to deliver integrated leadership, pharmaceutical innovation, and the next frontier of pharmaceutical portfolio strategy. Its flagship product, BioPharmaGPS, uses AI to integrate external industry shifts, multi-market signals, and internal organizational knowledge into live strategic and operational roadmaps for biotechnology and pharmaceutical professionals.
Media Contact
Samiksha Shah [samiksha.shah@whatsnextforpharma.com]
